{
    "clinical_study": {
        "@rank": "156290", 
        "arm_group": {
            "arm_group_label": "Arterakin", 
            "arm_group_type": "Other", 
            "description": "Number of  DHA- PPQ (Arterakin\u2122)  tablets per day at 0hour, 8hours, 24hours, 48hours (according to age): 2 - 3  years:0.5, 0.5, 0.5, 0.5 3 - < 8 years: 1.0, 1.0, 1.0, 1.0 8 - < 15 years:1.5, 1.5, 1.5, 1.5\n\u2265 15 years:2.0, 2.0, 2.0, 2.0"
        }, 
        "brief_summary": {
            "textblock": "Resistance of Plasmodium falciparum toward Artemisinins, the most important drug for the\n      successful treatment of malaria, has been confirmed in Cambodia. There are few reports from\n      neighbouring countries about delayed parasite rates. The investigators therefore aim to\n      assess parasite clearance in malaria patients in central Vietnam when treated according to\n      national standard guidelines."
        }, 
        "brief_title": "Plasmodium Falciparum Artemisinin Resistance Vietnam", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Plasmodium Falciparum", 
        "detailed_description": {
            "textblock": "General objective To evaluate the efficacy of DHA-PPQ in patients with uncomplicated\n      falciparum malaria in a rural area of Central Vietnam, and to assess the in vitro\n      susceptibility of P.falciparum isolates to DHA and PPQ.\n\n      Specific objectives\n\n        1. To measure the parasite clearance time in falciparum malaria patients treated with\n           DHA-PPQ.\n\n        2. To determine the efficacy of DHA-PPQ at day 42 post-treatment.\n\n        3. To assess the in vitro susceptibility of P.falciparum isolates towards DHA  and PPQ in\n           Quang Nam Province.\n\n        4. To compare genetic profiles of P.falciparum isolates with delayed and those with normal\n           clearance times in order to identify potential markers of resistance;"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age:  from 6 months of age;\n\n          -  Fever (body temperature above 37.5C) or history of fever in the previous 24 hours;\n\n          -  Mono-infection with P.falciparum with parasite density between 500-100,000/\u00b5l\n\n          -  Written informed consent to participate to the trial. For patients aged less than 18\n             years, an informed consent will be obtained from a parent or a guardian.\n\n        Exclusion Criteria:\n\n          -  Mixed malaria infection;\n\n          -  Pregnancy or lactation (urine test for \u03b2 human chorionic gonadotropin to be performed\n             on any woman of child bearing age unless menstruating);\n\n          -  Concomitant acute illness necessitating specific treatment (antibiotics);\n\n          -  Underlying chronic severe illness (e.g. cardiac, renal, hepatic diseases, HIV/AIDS).\n\n          -  Severe malnutrition;\n\n          -  Danger signs:\n\n               -  not able to drink\n\n               -  incontrollable vomiting\n\n               -  recent history of convulsions (>1 in 24 hours)\n\n               -  unconscious state; neurological impairment\n\n               -  unable to sit or stand\n\n          -  Signs of severe malaria:\n\n               1. Cerebral malaria (unrousable coma)\n\n               2. Severe anaemia (Htc< 15%)\n\n               3. Renal failure (serum creatinine > 3 mg/dL)\n\n               4. Pulmonary oedema;\n\n               5. Hypoglycemia (<40mg/dL)\n\n               6. Shock (systolic BP < 70 mmHg in adults, 50 in children)\n\n               7. Spontaneous bleeding\n\n               8. Repeat generalized convulsions\n\n               9. Macroscopic haemoglobinuria\n\n              10. Severe jaundice\n\n          -  Persons who have received quinine, artemisinin or artemisinin derivatives within the\n             last 7 days, 4-aminoquinolines within the last 14 days, pyrimethamine and/or\n             sulfonamides within the last 28 days, or mefloquine within the last 56 days should be\n             excluded from the in vitro testing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "95", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775592", 
            "org_study_id": "NIMPE - ITM"
        }, 
        "intervention": {
            "arm_group_label": "Arterakin", 
            "description": "NA", 
            "intervention_name": "Arterakin (DHA-PPQ)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "P.f resistance", 
        "lastchanged_date": "January 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tra Leng", 
                    "country": "Vietnam", 
                    "state": "Quang Nam"
                }, 
                "name": "Health Centre Tra Leng"
            }
        }, 
        "location_countries": {
            "country": "Vietnam"
        }, 
        "number_of_arms": "1", 
        "official_title": "Monitoring the Efficacy of Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Traleng Commune, Central Vietnam", 
        "other_outcome": {
            "description": "genotyping", 
            "measure": "genetic profiles of P.falciparum isolates with delayed and those with normal clearance times in order to identify potential markers of resistance", 
            "safety_issue": "No", 
            "time_frame": "1year"
        }, 
        "overall_official": {
            "affiliation": "ITM", 
            "last_name": "Annette Erhart, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Vietnam: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Parasite clearance time", 
            "safety_issue": "No", 
            "time_frame": "Day 2-5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775592"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "treatment failure or success at day 42", 
                "measure": "efficacy of DHA-PPQ at day 42 post-treatment in Traleng Quangnam, Vietnam", 
                "safety_issue": "No", 
                "time_frame": "Day 42"
            }, 
            {
                "description": "MarkIII in vitro test", 
                "measure": "in vitro susceptibility of P.falciparum isolates towards DHA  and PPQ in Quang Nam Province", 
                "safety_issue": "No", 
                "time_frame": "Day 3-10"
            }
        ], 
        "source": "National Institute of Malariology, Parasitology and Entomology, Vietnam", 
        "sponsors": {
            "collaborator": {
                "agency": "Institute of Tropical Medicine, Belgium", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Malariology, Parasitology and Entomology, Vietnam", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}